This invention relates to sulfated glycopolymers comprising a polymeric backbone wherein at least one of the monomeric units which form the backbone has a pendant galactose and/or N-acetyl galactosamine group, wherein one or more of the pendant galactose groups are sulfated at one or more of positions 2, 3, 4 and 6 and/or one or more of the N-acetyl galactosamine groups are sulfated at one or more of positions 3, 4 and 6. The invention also relates to the use of sulfated glycopolymers in the treatment of a disease, for example, IRI, acute kidney injury, myocardial ischaemia, ischaemic stroke, cancer or an autoimmune disease.